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Abstract
Background:  Phenylethanolamines selectively bind to NR2B subunit-containing N-methyl-D-
aspartate-subtype of ionotropic glutamate receptors and negatively modulate receptor activity. To
investigate the structural and functional properties of the ifenprodil binding domain on the NR2B
protein, we have purified a soluble recombinant rat NR2B protein fragment comprising the first
~400 amino acid amino-terminal domain (ATD2B) expressed in E. coli. Spectral measurements on
refolded ATD2B protein demonstrated specific binding to ifenprodil. We have used site-directed
mutagenesis, circular dichroism spectroscopy and molecular modeling to obtain structural
information on the interactions between critical amino acid residues and ifenprodil of our soluble
refolded ATD2B proteins. Ligand-induced changes in protein structure were inferred from changes
in the circular dichroism spectrum, and the concentration dependence of these changes was used
to determine binding constants for ifenprodil and its analogues.
Results: Ligand binding of ifenprodil, RO25,6981 and haloperidol on soluble recombinant ATD2B
determined from circular dichroism spectroscopy yielded low-to-high micromolar equilibrium
constants which concurred with functional IC50 measurement determined in heterologously
expressed NR1/NR2B receptors in Xenopus oocytes. Amino acid residue substitutions of Asp101,
Ile150 and Phe176 with alanine residue within the ATD2B protein altered the recombinant protein
dissociation constants for ifenprodil, mirroring the pattern of their functional phenotypes.
Molecular modeling of ATD2B as a clam-shell-like structure places these critical residues near a
putative ligand binding site.
Conclusion: We report for the first time biochemical measurements show that the functional
measurements actually reflect binding to the ATD of NR2B subunit. Insights gained from this study
help advance the theory that ifenprodil is a ligand for the ATD of NR2B subunit.
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Background
N-methyl-D-aspartate (NMDA) receptors are postsynaptic
receptors for L-glutamate, the major excitatory neuro-
transmitter in the central nervous system. They are ligand-
gated ion channels that are permeable to K+, Na+ and Ca2+.
They play a pivotal role in neuronal development, synap-
tic plasticity, and learning and memory [1-5]. However,
the overactivation of these receptors has been implicated
in excitotoxic neuronal cell death observed in neurologi-
cal disorders such as stroke, epilepsy [6,7] and head
trauma [8].
NMDA receptors are heteromeric structures composed of
an obligatory NR1 subunit and one or more of the four
NR2 subunits (NR2A-D) and/or NR3 subunits (NR3A-B)
[9-12]. Each NMDA receptor subunit shares a characteris-
tic modular architecture with three transmembrane seg-
ments (M1, M3 and M4), a re-entrant loop (initially
known as M2) which forms the pore-lining region, an
intracellular C-terminal domain, and large extracellular
domains [5,10,12]. The large extracellular domains of the
mature NR2B subunit include amino acids 27–557
(Accession number U11419) situated pre-M1 and amino
acids 649–817 between M3 and M4. The glutamate bind-
ing pocket is made up of two discontinuous stretches of
amino acids encoded by the S1 and S2 regions of cDNA.
Each segment constitutes ~150 amino acids preceding M1
and following M3. The remaining non-agonist binding
segment preceding M1 is also known as the amino-termi-
nal domain (ATD) (Fig. 1A).
Expression of isolated domains has been applied to lig-
and-gated glutamate receptors, voltage-gated potassium
ion channels and many other plasma membrane bound
ion channels and receptors with reasonable success. For
NMDA receptors, the crystal structures of the ligand bind-
ing core (S1S2) for glycine (NR1) and glutamate (NR2A)
have been successfully solved recently [13,14]. These
atomic structures provide, for the first time, a bridge
between data obtained from biophysical, molecular and
biochemical studies of NMDA receptors. There are now
over 50 crystal structures of various glutamate receptor
binding cores bound to different ligands [15-19].
In contrast, there is no crystal structure for the putative
allosteric modulators' binding sites located on the amino
terminal domain proximal to the S1 region of ionotropic
glutamate receptors, including NMDA receptors. The
apparent high affinity Zn2+ binding site is situated in ATD
of NR2A [20-22]; the putative phenylethanolamines
binding site(s) in ATD of NR2B [23-25]; the polyamine-
sensitive region in ATD of NR1 [26,27]; and possibly a
Zn2+ binding site in NR2B [28]. Indeed, Rosahl and col-
leagues [25] provided ex vivo support for the modulatory
role of ATD of NR2B by ifenprodil and ifenprodil-like
NMDA receptor antagonists recently. By replacing the
mouse NR2B gene function by "knocking-in" a chimeric
human NR2A/B cDNA containing ATD of NR2A fused to
the endogenous NR2B locus, the high affinity component
from the inhibition of NR2B containing receptors was
absent in culture hippocampal neurons.
Like the ATD of NR2A subunit of NMDA receptor which
binds the negative allosteric modulator Zn2+ [20-22,29],
NR2B ATD binds negative modulator phenyleth-
anolamines and analogues (ifenprodil, RO25,6981,
haloperidol) (Fig. 1B) [23,24,30-34]. The NMDA receptor
subunit ATD is a large domain made up of the first ~400
amino acids (e.g. residues 27–403) of the mature
polypeptide. The ATD has weak homology and shows
similarities in predicted secondary structure with bacterial
periplasmic leucine/isoleucine/valine-binding protein
(LIVBP) [27,35]. NMDA receptor ATD also shares homol-
ogy and predicted secondary structure with the G-protein-
coupled metabotropic glutamate receptor 1 (mGluR1),
for which the crystal structure of the glutamate binding
Modular organization of NR2B subunit of NMDA receptor Figure 1
Modular organization of NR2B subunit of NMDA 
receptor. A. Diagram shows the amino-terminal domain 
(ATD), the two lobes (S1–S2) comprising the glutamate bind-
ing domain, the three transmembrane domains (M1, M3 and 
M4), the re-entrant loop and the intracellular cytoplasmic 
terminus (-COOH). ATD has been proposed to harbor the 
binding site for phenylethanolamines such as ifenprodil. B. 
Chemical structures of ifenprodil, RO25,6981 and haloperi-
dol – ligands that bind to and negatively modulate the current 
flux through NR2B subunit-containing NMDA receptors.Molecular Brain 2008, 1:16 http://www.molecularbrain.com/content/1/1/16
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domain is known [36]. There is no crystallographic struc-
tural information on the ATD of NMDA receptor or any
other ionotropic glutamate receptors at atomic resolution.
This has slowed advances in our understanding about
how the negative modulators inhibit the opening of the
NMDA receptor channel, which is triggered by glutamate
binding to the agonist binding core [37]. However, several
low level electron microscopy studies suggest an orienta-
tion of ATD with respect to the glutamate binding core in
AMPA receptors [38-40].
To begin to address this gap in our understanding, we
have constructed and expressed the modular amino-ter-
minal domain (proximal 367 amino acids) of NR2B sub-
unit (ATD2B) as a 6xHis-fusion protein (6 × His-ATD2B)
in Escherichia coli expression system [41]. In this study, we
demonstrate, for the first time, that soluble 6 × His-
ATD2B recombinant proteins can bind various modula-
tors with dissociation constants (KDs) close to and corre-
lated tightly with the functional IC50  measurements.
Mutations at the critical amino acids (Asp101, Ile150,
Phe176) within ATD of NR2B subunit significantly
decrease the binding affinity of ifenprodil to 6 × His-
ATD2B. Three-dimensional homology model of the ATD
of NR2B revealed that these critical amino acids are strate-
gically positioned around the putative ligand binding
cleft. Taken together, our multi-disciplinary approach
supports the concept of a modular organization of ATD
within the NR2B subunit as well as its inherent ability to
bind negative allosteric modulating ligands.
Results
Buffers -9, -12 and -13 refolded ATD of NR2B
Using a fractional factorial folding screen [41,42], we had
successfully refolded 6 × His-ATD2B recombinant protein
in three buffers differing in pH, refolding temperature,
divalent ions, polar and nonpolar additives, chaotrope,
GSH:GSSH ratio, detergent, PEG, and presence/absence of
a ligand. These buffers were described in our previous
work [see Additional file 1], and are referred to here by the
same nomenclature as that study (Buffers -9, -12 and -13
[41]). We had shown previously Buffer-13 refolded 6 ×
His-ATD2B existed in a soluble and monodispersed spe-
cies which bound ifenprodil in a concentration-depend-
ent manner (KD = 128 nM) [41].
In this study we examine the structural and functional
properties of refolded recombinant 6 × His-ATD2B pro-
teins. Light scattering detection analysis allows biomo-
lecular sizing and characterization of proteins to be
measured directly. Dynamic light scattering analyses
showed Buffers -9 and -12 refolded 6 × His-ATD2B pro-
teins existed in monodispersed species (data not shown).
Their relative percentages of α-helix content were esti-
mated to be 26.7 ± 0.4% (n = 5) and 27.7 ± 0.7% (n = 6),
respectively. These values were congruent with the 26.8%
estimated for Buffer-13 refolded protein reported previ-
ously [41].
Circular dichroism (CD) spectroscopy is a useful tech-
nique for studying protein-protein interactions in solu-
tion [43]. Circular dichroism spectroscopy measures
differences in the absorption of left-handed polarized
light versus right-handed polarized light. Units given are
typically ellipticity (theta, θ), which is related to the differ-
ence in absorbance of left and right circularly polarized
light. This difference arises from the interaction between
the light and the chiral nature of the protein structure. The
chromophore for wavelengths in the "far-UV" spectral
region (190–250 nm) is the peptide bond, and the signal
arises when it is located in a regular, folded environment.
Secondary structural elements such as alpha-helix, beta-
sheet, and random coil structures each give rise to a char-
acteristic shape and magnitude of CD spectrum. The CD
spectrum of a protein in the "near-UV" spectral region
(250–350 nm) can be sensitive to the overall tertiary
structure of the protein, including signals for phenyla-
lanine (250–270 nm), tyrosine (270–290 nm), and tryp-
tophan (280–300 nm), as well as weak signals from
disulfide bonds throughout the near-UV spectrum. Thus,
evaluation of changes in the CD spectrum can be used to
monitor changes in protein conformations following lig-
and binding, and the concentration dependence of lig-
and-induced changes in the CD spectrum can also be used
to estimate binding affinities [44-46].
CD spectra of the Buffers -9 (Fig. 2A) and -12 refolded
(Fig. 2B) 6 × His-ATD2B proteins were obtained in the
presence of 5 μM ifenprodil and 0.5 μM RO25,6981.
Ifenprodil and RO25,6981 in the concentration ranges
0.01–5 μM and 0.002–0.5 μM, respectively, diminished
the θ over the wavelengths in the region 210–250 nm.
We interpret the concentration-dependent shifts of mag-
nitude at wavelength 220.0 nm ellipticity to suggest that
ifenprodil binds to refolded soluble 6 × His-ATD2B pro-
teins with KD values of 60 ± 18 nM for Buffer-9 (n = 5,
Fig. 3A) and 61 ± 34 nM for Buffer-12 (n = 5, Fig. 3B).
The concentration-dependent changes in the CD spec-
trum induced by RO25,6981 (218.9 nm) upon interact-
ing with the 6 × His-ATD2B proteins suggest that the
ligand binds with KD values of 7 ± 3 nM (Buffer-9), 4 ± 1
nM (Buffer-12) (n = 5, Figs. 3C, D) and 4 ± 2 nM (Buffer-
13). Figure 4A summarizes the binding properties of 6 ×
His-ATD2B to ifenprodil and RO25,6981 between three
different protein refolding buffers. In addition, in the
presence of saturating concentration of 5 μM ifenprodil,
RO25,6891 could displace ifenprodil and bind to 6 ×
His-ATD2B with comparable affinities in the absence of
ifenprodil: Buffer -9 (4 ± 1 nM), Buffer -12 (2 ± 1 nM)
and Buffer -13 (3 ± 1 nM).Molecular Brain 2008, 1:16 http://www.molecularbrain.com/content/1/1/16
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Ligand Inhibition of Heterologously Expressed NR1/NR2B 
Receptors in Xenopus Oocytes
Ifenprodil and RO25,6981 are NR2B-selective antago-
nists. Although both molecules share similar chemical
structures that are likely to act on the same putative bind-
ing site residing in the ATD of NR2B, RO25,6981 is more
potent than ifenprodil in inhibiting heterologously
expressed and native NR2B-containing NMDA receptors
(see [31] for review). We heterologously expressed NR1
with NR2B in Xenopus oocytes to determine the NMDA
receptor sensitivity to both ifenprodil and RO25,6981 so
as to establish the ratio of IC50(ifenprodil) to
IC50(RO25,6981). This ratio will determine which buffer-
refolded 6 × His-ATD2B (ie. Buffer-9 vs Buffer-12 vs
Buffer-13) will be used for detail binding analyses. The
negative allosteric antagonists inhibited NR1/NR2B
receptor current responses with IC50 values 105 nM and
59 nM at pH7.3, respectively (Fig. 4B; Table 1). The ratio
of IC50(ifenprodil) to IC50(RO25,6981) is almost 2.
6 × His-ATD2B Binds Antipsychotic Drug Haloperidol
6 × His-ATD2B refolded in Buffer-9 was able to bind a
number of ligands with a wide range of affinities.
Haloperidol, a dopaminergic antagonist with antipsy-
chotic properties, is also known to block NR2B-contain-
ing NMDA receptors at micromolar concentrations [47-
49]. Analysis of changes in CD spectra suggested that
haloperidol bound to Buffer-9 refolded 6 × His-ATD2B in
a dose-dependent manner. The maximum magnitude
shift in ellipticity over 0.1–30 μM of haloperidol at 219.6
nm yielded a KD of 3094 nM (Table 1).
If the KD values estimated for the various ligands tested
accurately represent dissociation equilibrium constants,
then the biochemically determined KD values should cor-
relate well with the IC50 values determined in functional
assays. To address this, we performed linear regression
analysis of three ligands with wide apart affinities (60–
440 fold, Table 1; also see [48] and [34]) on our experi-
mentally determined IC50  and KD. The ability of our
Buffer-9 refolded 6 × His-ATD2B protein to bind three lig-
ands of widely varying affinities (ifenprodil, RO25,6981
and haloperidol) yielded a tight correlation (R = 0.96; Fig.
4C). This strong linear correlation provided additional
evidence that our soluble recombinant protein assumed a
conformation that could bind its specific ligands.
Computing the ratios of KD(ifenprodil) to
KD(RO25,6981) for each refolding buffers showed
approximately 9-fold for Buffer-9, 15-fold for Buffer-12
and 24-fold for Buffer-13 refolded 6 × His-ATD2B pro-
teins (Fig. 4A; Table 1). Buffer-9 refolded 6 × His-ATD2B
Representative CD spectra of soluble 6 × His-ATD2B pro- teins in the presence and absence of ligands at 25°C Figure 2
Representative CD spectra of soluble 6 × His-ATD2B 
proteins in the presence and absence of ligands at 
25°C. A. Buffer -9 refolded protein; B. Buffer -12 refolded 
protein; Solid line, protein in absence of ligand; Dotted line, 
in presence of 5 μM ifenprodil; Dashed line, in presence of 
0.5 μM RO25,6981; Dashed-dotted line, 4 M Gdn.HCl-dena-
tured protein. Y-axis represents the molecular ellipticity. X-
axis represents the range of wavelengths analyzed.
Ifenprodil and RO25,6981 titration curves of soluble 6 × His- ATD2B proteins Figure 3
Ifenprodil and RO25,6981 titration curves of soluble 
6 × His-ATD2B proteins. A. Buffer -9 refolded protein in 
the presence of ifenprodil; B. Buffer -12 refolded protein in 
the presence of ifenprodil; C. Buffer -9 refolded protein in 
the presence of RO25,6981; D Buffer -12 refolded protein in 
the presence of RO25,6981. The results are the average of 
five experiments using proteins obtained from at least two 
independent batches of bacteria induction. Error bars repre-
sent S.E.Molecular Brain 2008, 1:16 http://www.molecularbrain.com/content/1/1/16
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yielded a ratio closest to the relative potency (IC50 ratio of
2) of ifenprodil to RO25,6981 (Fig. 4B and Table 1). Thus,
subsequent structural and functional characterizations of
the modular ATD of NR2B were performed on Buffer-9
refolded 6 × His-ATD2B protein.
Impaired Binding Interactions between Recombinant 
ATD2B Mutants and Ifenprodil
We next sought to more directly evaluate the ifenprodil
binding pocket of Buffer-9 refolded 6 × His-ATD2B. A
charged (Asp101), an aliphatic (Ile150) and an aromatic
(Phe176) amino acid residues, previously reported to be
critical molecular determinants for ifenprodil inhibition
of NR2B-containing NMDA receptors (> 60-fold increase
in IC50 values compared to wild-type NR1/NR2B recep-
tors; [23]), were mutated to alanine (designated as
ATD2B(D101A), ATD2B(I150A), ATD2B(F176A)) using
site-directed mutagenesis (see Methods). We subjected
these mutant 6 × His-ATD2B proteins to increasing con-
centrations of ifenprodil to evaluate the concentration
dependence of binding. In the presence of increasing
amounts of ifenprodil, each mutant protein D101A and
I150A yielded higher KD values of 173 nM and 139 nM,
respectively (Table 2). By substituting phenylalanine with
alanine at amino acid 176, the concentration-effect curve
yielded even higher KD value of 331 nM (Fig. 5A solid cir-
cle). When compared to the wild-type (WT) ATD2B pro-
tein, these mutations caused a 2.9- (D101A), 2.3- (I150A)
and 5.5- (F176A) fold increase in KD values, which were
statistically significant (P < 0.05) (Fig. 5C and Table 2).
We hypothesized that ifenprodil binding would destabi-
lize further if more than one of the several key amino acid
residues, whose side chain may make Van der Waals or
hydrogen bonding contact with the ligand, were removed.
We selected the charged Asp101 and hydrophobic Phe176
residues to disrupt jointly in our recombinant ATD2B pro-
tein. D101A was inserted into ATD2B(F176A) plasmid
using overlap extension site-directed mutagenesis (see
Methods). Indeed, this double mutant recombinant pro-
tein ATD2B(D101A/F176A) displayed a much weaker
binding to ifenprodil (KD 627 nM compared to 60 nM
WT; P < 0.05; Fig. 5A, C; Table 2).
Molecular Modeling of the Amino-Terminal Domain of the 
NR2B Subunit
To better understand the structural determinants of ligand
binding to ATD of NR2B, we used Prime Structure Predic-
tion (Schrödinger) to build a homology model of ATD2B
Bar chart showing the relative affinities of ifenprodil and  RO25,6981 towards the three buffers' refolded 6 × His- ATD2B proteins Figure 4
Bar chart showing the relative affinities of ifenprodil 
and RO25,6981 towards the three buffers' refolded 6 
× His-ATD2B proteins. A. Results are the average of five 
experiments using proteins obtained from at least two inde-
pendent batches of bacteria induction. Error bars represent 
S.E. Ratios of KD(ifenprodil) to KD(RO25,6981) are 9 (Buffer-
9), 15 (Buffer-12) and 24 (Buffer-13), respectively. B. Com-
posite antagonists' inhibition curves are shown for NR1 
coexpressed with wild-type NR2B in Xenopus oocytes. Error 
bars represent ± SEM. C. The Log IC50 for RO25,6981, ifen-
prodil and haloperidol plotted against their respective Log 
KD values obtained from dose-titration using CD. A linear 
regression fit revealed good correlation (R = 0.96) between 
the mean Log IC50 and Log KD values for each ligand. The 
mean of the sum of individual log value obtained from each 
fitted dose-inhibition plot for each ligand and SEM are plot-
ted. Mean KD and IC50 values are given in Table 1.
Table 1: Binding properties of ligands to soluble 6 × His-ATD2B 
protein and their inhibition on heterologously expressed NR1-1a/
NR2B receptors in Xenopus oocytes.
Ligand KD(nM) IC50(nM)
RO25,6981 7 ± 3 (n = 5) 59 ± 1 (n = 22)
Ifenprodil 60 ± 18 (n = 5) 105 ± 9 (n = 20)
Haloperidol 3094 ± 940 (n = 5) 2762 ± 363 (n = 18)
Dose-titration binding constants of RO25,6981, ifenprodil and 
haloperidol performed on Buffer -9 refolded 6 × His-ATD2B protein 
determined from CD. Values are mean ± S.E. of the KD values from 
five experiments using proteins obtained from at least two 
independent batches of bacteria induction. Rat NR1 and NR2B 
subunits were coexpressed in Xenopus oocytes. NR2B-selective 
antagonists' inhibition of current responses induced by glutamate and 
glycine at pH7.3 were analyzed to obtain the mean-fitted IC50 values 
with n representing number of oocytes recorded.Molecular Brain 2008, 1:16 http://www.molecularbrain.com/content/1/1/16
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based on the crystal structure of mGluR1 agonist binding
domain complexed with glutamate (1 EWK; [36]). The
homology model of the ATD of NR2B in the apo (absence
of ligand) configuration is depicted in Fig. 6A. It is built
using the sequence alignment as shown in Additional file
2D. The α-helices and β-sheets were labeled according to
the mGluR1 structure [36]. Three (Asp101, Ile150 and
Phe176) out of four amino acids (Phe182) reported by
Perin-Dureau and colleagues [23] that played a critical
role in the inhibition of NR2B-containing NMDA recep-
tors (IC50(mutant)/IC50(WT) > 60) are highlighted in Fig.
6A. Examinations of these three "critical" molecular deter-
minants (D101A, I150A and F176A) reveal these residues
to be spatially distributed near a central cleft despite their
locations on different regions of the bi-lobed structure
(Asp101 on lobe I while Phe176 on lobe II) as well as on
the hinge region (Ile150) of the NR2B ATD (see also Fig.
8A in Perin-Dureau et al. [23]). Figures 6B and 6C show
these three critical residues to be located within the puta-
tive central cleft and in contact with the top-scoring pose
[50] of ifenprodil. In fact, ifenprodil is predicted to coor-
dinate with Asp101 and Phe176 via hydrogen and hydro-
phobic interactions. In addition, the docked pose has
significant Van der Waals contact with Val42, Thr103 and
Lys234, residues that all had a moderate effect in previous
studies [23] (data not shown).
Finally we searched for an amino acid residue located out-
side the cleft of the clam-shell conformation of NR2B
ATD. A charged residue, Asp113 located on lobe I, was
mutated and probed for its ligand binding phenotype (see
Fig. 6A). The D113A mutation showed nearly superim-
posable dose-dependent ifenprodil titration curve with a
KD similar to the wild-type soluble 6 × His-ATD2B (P >
0.4; Figs. 5B, C and Table 2).
Discussion
In the present work, we have used an autonomously
folded protein fragment of the amino terminal domain of
NR2B subunit to elucidate several critical residues that
influence the binding of putative modulators on the
mammalian NR2B subunit-containing NMDA receptors.
The two most important conclusions to emerge from this
study are that (1) the isolated ATD2B protein is sufficient
Ifenprodil titration curve for Buffer -9 refolded wild type and  mutant proteins Figure 5
Ifenprodil titration curve for Buffer -9 refolded wild 
type and mutant proteins. A. Average dose-titration plots 
showing reduced affinity of ifenprodil to the F176A mutant 
protein (n = 5) as compared to the wild type protein (n = 5). 
The mutant protein harboring double mutations D101A/
F176A (n = 5) (open circle) showed further reduction in 
affinity compared to the single mutant, F176A (filled circle). 
B. Mutation at residue Asp113, which was identified outside 
the putative ifenprodil binding pocket by our homology 
model, did not affect the binding affinity significantly (n = 5, P 
> 0.4). The KD values for different mutant proteins are listed 
in Table 2. Each data point is the average value obtained from 
five experiments using proteins obtained from at least two 
independent batches of bacteria induction. C. Mean-fitted KD 
values determined for WT protein and proteins containing 
the respective mutations. Paired Student t-Tests were per-
formed to evaluate the difference between mean of 
KD(mutant) and KD(WT), * P < 0.05.
Table 2: Comparison of KD values for the wild type and mutant 6 
× His-ATD2B proteins.
Protein KD (nM) Fold Shift
WT 60 ± 18 1
F176A 331 ± 122 5.5
D101A 173 ± 52 2.9
F176A/D101A 627 ± 295 10.5
I150A 139 ± 28 2.3
D113A 48 ± 15 0.8
Values are mean ± S.E. of the KD values from five experiments using 
proteins obtained from at least two independent batches of bacteria 
induction. The fold shift in KD values for each mutant is the ratio of 
KD(mutant) to KD(WT).Molecular Brain 2008, 1:16 http://www.molecularbrain.com/content/1/1/16
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to interact with various modulators with affinities that
correlate well with the physiological and biochemical
studies, and (2) the critical molecular determinants for
the binding of these modulators reside within the proxi-
mal ~400 amino acids preceding S1 domain of NR2B sub-
unit. These data provide direct confirmation of ligand
binding to ATD as well as suggest that mutations previ-
ously described influence the binding of ifenprodil, a
NR2B-selective modulatory ligand.
Comparison to previous studies
The KD values determined with CD spectroscopy of lig-
ands for ATD2B correlated with functionally determined
IC50 values (Fig. 4C), and were consistent with KD values
previously reported for [3H]ifenprodil binding to rat brain
cortex (KD = 36 nM) [51] and both NR1/NR2B transfected
HEK293 and mouse L(tk-) cell line (KD = 34–79 nM)
[52,53]. Furthermore, our ligand displacement experi-
ment using RO25,6981 (~9-fold higher KD affinity deter-
mined in this study) over ifenprodil on ATD2B protein
yielded Ki values (2–4 nM for Buffers -9, -12 and -13, n =
5 per buffer; details not shown) comparable to KD values
that were determined for RO25,6981 alone. Thus, our
findings on refolded ATD2B agree well with previous
determinations of ligand affinities determined in intact
receptors.
Previous description of alanine mutagenesis scan in the
NR2B ATD on key amino acid residues known to coordi-
nate ifenprodil and RO25,6981 binding [23,24] corrobo-
rated our structural findings. Perin-Dureau and colleagues
[23] showed that the substitutions of Asp101, Phe176 and
Phe182 produced the largest effects on ifenprodil potency
for inhibition of NR1/NR2B currents, and hypothesized
that these residues were involved in ifenprodil binding.
They further proposed that Ile150 participated in the
clam-shell closure mechanism rather than direct contact
with the ligand. D101A and F176A mutations inserted
individually into the full length NR2B subunit of the het-
erologously expressed NR1/NR2B receptors yielded > 60-
fold increase in IC50  values [23]. Our experimentally
determined KD  values for these two same mutations
inserted into our ATD2B refolded protein were 2.3–5.5
fold higher than those determined from wild-type ATD2B.
Our results are consistent with the ideas presented by
Perin-Dureau et al. [23], and suggest that these residues
can directly impact ifenprodil binding. However, the sin-
gle residue mutant ATD2B proteins did not generate the
same degree of shift in KD as observed for the IC50 value
determined from two electrode voltage clamp current
measurements. The IC50 values determined from the volt-
age clamp experiments describe the concentration-
dependence of ifenprodil reduction in cation flux through
the aqueous channel pore. This functional measure thus
takes into account the effects of mutations on allosteric
interactions between domains, long range intra-protein
interactions, in addition to effects on ligand binding site.
It seems likely that some of the differences in our KD and
functional IC50  values are attributed to the study of
ATD2B in isolation.
Our KD values, determined via dose-dependent ligand-
binding assay using CD, are 'snap-shots' physical con-
stants between the ligands and the isolated ATD protein.
Interestingly, D101A and F176A mutations resulted in
complete loss of [3H]RO25,6981 binding to membranes
of HEK293 cells transiently co-transfected with NR1 and
NR2B cDNAs [24]. Since both ifenprodil and RO25,6981
only differ chemically by a methylene between the piperi-
dine ring and the phenyl ring (see Fig. 1B), one plausible
scenario would be that other surrounding charged (eg.
Asp104) and hydrophobic (eg. Phe182) residues could
possibly compensate partially for the substituted Asp101
and Phe176, respectively [23]. Alternatively, both ligands
may dock themselves in an opposite manner into the
Homology model of ATD of NR2B subunit Figure 6
Homology model of ATD of NR2B subunit. A. Ribbon 
representation of the amino-terminal domain of NR2B was 
constructed as described under Materials and Methods using 
mGluR1 crystal structure (1 EWK) as template [36]. Model 
resembles the clam-shell configuration as seen in the bacte-
rial periplasmic leucine-isoleucine-valine binding protein 
(LIVBP) (2 LIV). Critical residues (Asp101, Ile150, Phe176) 
that reduced ifenprodil sensitivity 60-fold and more, when 
mutated, as compared to wild-type NMDA receptors [23] 
are shown as red sticks using Rasmol. A mutation (D113A) 
outside the putative ifenprodil binding pocket is identified by 
blue sticks. B. Putative ifenprodil binding pocket highlighting 
the three critical amino acid residues that play critical role in 
interacting with ligand and the inhibition sensitivity of NR2B-
containing NMDA receptors. C. Ifenprodil-docked into 
ATD2B putative binding pocket model. The relative orienta-
tions of side chains of Asp101 (top red residue in red sticks), 
Ile150 and Phe176 towards the putative centre cleft suggest 
plausible ligand-protein interactions with various functional 
groups on ifenprodil (see Discussion).Molecular Brain 2008, 1:16 http://www.molecularbrain.com/content/1/1/16
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binding pocket within ATD2B. Notwithstanding these
discrepancies, our experimental data on double-mutant
ATD2B(D101A/F176A) recombinant protein, as pre-
dicted, yielded larger shift in its KD. The degree of this
reduction in affinity for the double-mutant protein in
association with ifenprodil is more than an additive effect
when compared to single amino acid substitutions of
D101A or F176A.
Molecular features of ifenprodil binding and inhibition
Our homology model shows a clam-shell configuration of
NR2B ATD with a central cleft. The carboxyl of Asp101
and the hydrophobic phenyl ring of Phe176, from lobe I
and lobe II respectively, are located within the microenvi-
ronment of the cleft (Fig. 6B). The carboxyl group of
Asp101 can potentially interact with the basic nitrogen on
the piperidine ring, or either of the hydroxyl groups of
ifenprodil via electrostatic interactions or hydrogen bond-
ing. The phenyl rings of Phe176 and ifenprodil can estab-
lish hydrophobic interaction (Fig. 6C). The predicted
distance between these two residues from our model is
11.2 Å (γ-carbon to γ-carbon). In the homology model,
Ile150 is located at the end of one of three flexible loops
that link Lobe I and Lobe II of the ATD. Together with
other critical residues such as Phe176 and Phe182, its
alkyl side chain helps form a hydrophobic backing to the
pocket where ifenprodil and RO25,6981 are predicted to
dock (Fig. 6C). As such, it is plausible to hypothesize that
Ile150 and Phe182 potentially provide contact to ligands
through nonspecific lipophilic interactions [23]. Ile150
and Phe182 may also provide a hydrophobic environ-
ment that helps organize other nearby residues such as
Phe231 or Val258, or they may provide a limit on the
length of the ligand (the phenol end) as McCauley and
colleagues observed of large non-polar hydrophobic side
chains larger than methyl at the phenol end of ifenprodil-
like compounds, which have poor inhibitory properties
on NR1/NR2B expressing cell lines [53]. In contrast to
elongated binding poses with the ligand stretched across
the cleft as seen in Marinelli et al. [54], the formation of a
deep pocket allows the ligand to bury some of its hydro-
phobic regions as well as bringing it into proximity with
other residues shown to be critical for binding.
Conclusion
We have provided evidence for the binding of ifenprodil
and its analogues directly to soluble recombinant ATD
protein of NR2B subunit. We have also provided data sup-
porting the direct involvement of intra-cleft residues pre-
dicted by a homology model of ATD2B in ifenprodil
binding and developed a proposed binding mode that
more clearly demonstrates the role of these residues.
These show that the soluble folded ATD2B protein pro-
vides a new tool for structure-activity studies on existing
and new subunit selective modulators that bind to gluta-
mate receptor amino terminal domains [55].
Methods
Materials
Rat cDNAs for NR1-1a (hereafter NR1) and NR2 subunits
(GenBank numbers NR1 U11418 and U08261; NR2B
U11419) were provided by Dr. S. Heinemann (Salk Insti-
tute, La Jolla CA). The vector pET30b(+)EG was a gift from
Dr E. Gouaux (Vollum Institute, Portland OR). Ifenprodil,
RO25,6981 and haloperidol were obtained from Sigma.
Oligonucleotides were purchased from Metabion (USA)
and Proligo (Singapore).
Site-directed mutagenesis
Residues that are targeted by mutagenesis in ATD
sequence of NR2B subunit are shown in Additional file
2A. These amino acids were mutated in pET30b(+)EG-
ATD2B plasmid [41] by overlap extension site-directed
mutagenesis (D101A, I150A, F176A) [56,57] and Quik-
Change methods (D113A) [22]. The mutagenesis primers
used are listed in Additional file 3. For overlap extension
mutagenesis, two addition primers (2B-PRM5 and 2B-
PRM6) [41] were coupled to the above mutant primers to
first generate two amplicons with overlapping ends. The
authenticity of the full-length cloned inserts in all recom-
binant constructs was confirmed with dideoxy DNA
sequencing in both directions.
Wild-type and Mutant 6 × His-ATD2B Protein Expression, 
Solubilization, Purification and Refolding
The wild-type and mutant 6 × His-ATD2B recombinant
proteins were expressed, lyzed, solubilized, affinity-puri-
fied and refolded as described previously [41] [Additional
file 2B, C]). All proteins were finally dialyzed against
Buffer 2 [see Additional file 1]. The protein concentrations
of purified 6 × His-ATD2B were determined by Bradford
protein assay and absorbance at an extinction coefficient
(ε280 = 60,430 M-1cm-1) as reported previously [41].
Dynamic Light Scattering (DLS), Circular Dichroism (CD) 
Spectroscopy and Ligand-Binding Assay
DLS measurements were made with DynaPro (Protein
Solutions) and CD spectra were measured at 25°C on a
Jasco J-715 Spectropolarimeter equipped with a 0.1 cm
path-length cuvette (Jasco Corporation, Tokyo, Japan) as
described previously [41]. For the CD assays, the refolded
protein was concentrated to 1 mg/ml using Vivaspin 2 ml
concentrator (Vivascience). Ligand (haloperidol, ifen-
prodil or RO25,6981) was added in small aliquots from
stock solution to 350 μl of the protein solution. The final
change of assay volume was < 3% for all ligands investi-
gated. The CD spectra of the wild-type and mutant 6 ×
His-ATD2B proteins in the absence and presence of a lig-Molecular Brain 2008, 1:16 http://www.molecularbrain.com/content/1/1/16
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and were recorded from 190 to 250 nm. The CD spectrum
of Buffer 2 was subtracted from all the CD spectra
obtained. To ensure that the ligand molecules themselves
did not cause changes in the molecular ellipticities, con-
trol experiments were performed before the binding
assays whereby ligand was added into Buffer 2 and
scanned from 190 to 250 nm. CD spectra of all ligands
tested in this study did not give rise to noticeable absorb-
ance (data not shown). All experiments were performed
using at least two separate batches of induced and
refolded 6 × His-ATD2B proteins (both wild-type and
mutants), each batch in duplicates or triplicates. The dose-
dependent binding curves of ligands to 6 × His-ATD2B
were fitted by the following equation:
Y = Bmax [ligand]/(KD + [ligand])
where Y is the shift in ellipticity, [ligand] is the concentra-
tion of ligand investigated and KD is the dissociation equi-
librium constant.
Electrophoresis and Mass Spectrometry
The wild-type and all mutant recombinant 6 × His-ATD2B
proteins were separated, detected by specific antibodies
recognizing hexahistidine tag (Clontech; 1:10,000) and
N-terminal amino acids 27–76 of the NR2B subunit
(Santa Cruz Biotechnology, Inc; 1:500). Detection of the
primary antibody was performed with anti-rabbit IgG
horseradish peroxidase (HRP) (1 mg/ml) followed by
ECLPlus Western blotting detection reagents (Amersham
Pharmacia, USA). Molecular weights of proteins were con-
firmed by MALDI-TOF MS analysis (Voyager DE-STR,
Applied Biosystems). Trypsin-digested peptides of 6 × His-
ATD2B were analyzed on 4700 Proteomic Analyzer
(Applied Biosystems) and Data Explorer software [41].
Voltage-Clamp Recordings from Xenopus Oocytes
cRNA for rat NR1-1a (hereafter NR1) and NR2B were syn-
thesized in vitro and injected (5–10 ng) into stage V-VI
Xenopus laevis oocytes, isolated as previously described
[22,26,58]. Two-electrode voltage-clamp current record-
ings were made 2–7 days post injection. The recording
solution contained (in mM) 90 NaCl, 3 KCl, 10 HEPES,
0.5 BaCl2, 0.01 EDTA, 0.05 glycine (23°C); pH was
adjusted to 7.3 with NaOH. EDTA (10 μM) was added to
chelate contaminant extracellular divalent ions, including
trace amounts of Zn2+. Solution exchange was computer
controlled through an 8-modular valve positioner (Dig-
ital MVP Valve, Hamilton Company, Reno, NV). Voltage
and current electrodes were filled with 0.3 and 3.0 M KCl,
respectively, and current responses recorded at a holding
potential of -40 mV. Data acquisition and voltage control
were accomplished with a two-electrode voltage-clamp
amplifier (OC-725, Warner Instruments, Hamden, CT).
Data were pooled among oocytes and mean composite
concentration-effect curve was fitted by the following
equation:
Percent response = 100 - minimum/(1 + ([antagonist]/IC50)n) 
+ minimum
where IC50 is the concentration of antagonist that pro-
duces a 50% inhibition, [antagonist] is the concentration
of antagonist investigated, minimum  a residual current
response fixed to 0 and n is the Hill slope.
Homology Modeling and Docking
The protein sequence of the rat NR2B ATD (GenBank
accession number U11419) was aligned against that of
mGluR1 ATD (1 EWK; (36)) using a previously published
alignment [24] [Additional file 2D]. Both the open and
closed forms of mGluR1 were used as a structural basis for
homology models, but due to recent work the closed
model was used as the basis for docking [54]. The homol-
ogy model was then built from this modified alignment
using Prime (Schrödinger), and then subjected to multi-
ple iterative rounds of energy minimization and side
chain optimization to relieve any steric strain present in
the model. Ifenprodil was constructed in Maestro
(Schrödinger) and docked into the homology model
using Glide (Schrödinger) and induced fit docking, with
the box centered on residues Asp101, Asp104, Ile150,
Phe176, Phe182, and Thr233. Docking was constrained
by required contact with a previously identified critical
residue (Asp101) [23]. These results were then rescored
using the MM-GBSA protocol, which incorporates solva-
tion and protein relaxation.
Data Analysis
The shifts in ellipticities at 218.9 nm (RO25,6981), 219.6
nm (haloperidol) and 220 nm (ifenprodil), where the sig-
nal change on ligand binding was maximal, were calcu-
lated. The experiment data were analyzed by nonlinear
curve fitting (ORIGIN7, USA). All pooled data were
expressed as mean ± SEM. The numbers of CD assay for
wild-type and mutants as well as the number of oocytes
recorded on heterologously expressed NR1/NR2B recep-
tors are shown in parentheses.
Abbreviations
NMDA: N-methyl-D-aspartate; ATD: amino-terminal
domain; LIVBP: leucine-isoleucine-valine-binding pro-
tein; DLS: dynamic light scattering; CD: circular dichr-
oism; KD: dissociation constant.
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6xHis-ATD2B probed with anti-6xHis (left) and anti-NR2B  (right) pri-
mary antibodies. D. Rat NR2B and mGluR1 ATD sequence  alignment 
(CLUSTAL W 1.83) and secondary structure assignment based on  
mGluR1 [36]. Helices are shown as red cylinders, strands as blue arrows,  
with the same labeling as in Fig. 2 of [36]. Intraprotomer disulphide  
bridges identified in mGluR1 are indicated by thin solid black lines  con-
necting cysteines. Red amino acid residues indicate selected critical  
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